Skip to main content
. 2018 Aug 1;153(10):e182721. doi: 10.1001/jamasurg.2018.2721

Figure. Early Tumor Recurrence and Overall Survival Between Patients Receiving Antiviral Treatment (AVT) and Not Receiving AVT After Hepatectomy for Hepatitis B Virus–Related Hepatocellular Carcinoma.

Figure.

A, For patients receiving AVT, the 6-month, 1-year, and 2-year recurrence rates were 14.2%, 24.6%, and 38.5%, respectively; for patients not receiving AVT, recurrence rates were 23.4%, 37.1%, and 52.3% (P < .001). B, Overall 1-year, 3-year, and 5-year recurrence rates for patients receiving AVT were 24.7%, 50.7%, and 57.9%, respectively; for patients not receiving AVT, recurrence rates were 37.1%, 61.5%, and 70.8% (P < .001). C, Patients receiving AVT had better survival than patients not receiving AVT, with the corresponding 1-year, 3-year, and 5-year overall survival rate of 93.1%, 78.9%, and 69.1%, respectively, vs 87.6%, 68.4%, and 56.3% (P < .001).